Breast Cancer Awareness Month 2024: Advocacy Guide

“To me, it’s unethical to tell someone, ‘You have an increased risk of cancer, and here’s what you should be doing,’ and then they can’t access it. So that is a big part of our policy mission at FORCE—increasing access to care and reducing health disparities.”

Lisa Schlager, Vice President, Public Policy at FORCE

Access to care has become a top issue in the hereditary cancer community now that genetic testing has become so widely available. This is especially of concern for previvors, individuals with a known genetic risk of cancer but who have not been diagnosed with the disease, and survivors, who may be at heightened risk of other types of cancer as well as recurrence. Just this year, the National Cancer Institute (2024) reported that “up to 10 percent of all cancers may be caused by inherited genetic changes.”

Vice president of public policy at FORCE (Facing Our Risk of Cancer Empowered) Lisa Schlager shared, “We can get most people access to genetic testing these days for little or no money…But the issue becomes the downstream care.”

This begs the question of the morality of testing. How ethical is it to test for a genetic predisposition for a disease like breast cancer when the neccessary “downstream care” —which can include early initiation of screenings such as mammograms and MRIs to chemo-prevention and risk-management surgeries—may not be accessible or affordable?

There is a responsibility that comes with providing access to knowledge without the requisite support, guidance, and care that information will require.

In honor of Breast Cancer Awareness Monty, Lisa Schlager generously spoke with MedicalTechnologySchools.com about the top priorities in her advocacy work as vice president of public policy at FORCE, Facing Our Risk of Cancer Empowered.

Meet the Expert: Lisa Schlager, Vice President, Public Policy at FORCE

Lisa Schlager

Lisa Schlager has been the vice president of public policy for FORCE, Facing Our Risk of Cancer Empowered, since 2008. She found the organization after learning that she carries the BRCA1 mutation. One of dozens of mutations that place individuals at elevated risk of cancer, BRCA carries a high risk of breast, ovarian, prostate, and pancreatic cancers.

Of this experience Schlager shared, “ I was tested very, very early in the realm of genetic testing for this, in 1999, so these mutations had only been discovered a few years earlier, and in a lot of cases, were only being used in research. It happens that Sue Friedman, our founder, also was tested and learned of her mutation in those early days, the difference is that she had already been diagnosed with cancer. I had not.”

So it was Schlager’s experience as one of the earliest “previvors”—an individual with a known genetic risk for cancer but who has not been through the experience of cancer—that led her to this work.

Before being hired as VP of public policy, Schlager volunteered for FORCE, organizing support meetings as an outreach coordinator and representing the organization at national and local conferences.

Currently, her biggest passion is access to care.

The Needs

Navigating Care

The most pressing need within the hereditary cancer community is not simply access to care, but access to healthcare providers that have knowledge about genetics and know how to guide patients in decision-making. Though a firm believer in “knowledge is power” when navigating hereditary risk for cancer, Schlager shared that there are significant pros and cons that individuals need to consider before making the decision to undergo genetic testing.

Once confirmation of a genetic predisposition has been confirmed, previvors and survivors of hereditary cancers need healthcare providers who know how to evaulate risk, how to talk to patients about the implications, and how to guide them toward the best course of action.

Providers with such expertise will know the necessity of collecting data, including family histories that include third degree relatives. They’ll also know what tests to order and when to refer patients to specialists, and what kind, depending on the kind of mutation they carry and hence, the kinds of cancers for which they are at risk. This ideally includes a referral to a genetic counselor, but there are other health care providers trained to provide this service, such as nurses who have genetics certification or physicians with genetics expertise.

Dozens of mutations have been identified as placing carriers at increased risk for cancer. Drawing on her personal experience with the BRCA mutation, Schlager explained,

Each [mutation has] unique recommendations. But you might need to start breast cancer screening as early as 25. You might need to do things like breast MRIs, and in some cases, risk reducing surgery… especially if you’re high risk for ovarian cancer, because we do not have early detection for it. The only way to reduce risk effectively is to remove the ovaries and tubes…a BRCA1 one mutation carrier is recommended to remove ovaries and fallopian tubes between 35 and 40 versus a BRCA2 mutation carrier, between 40 and 45. Other mutations might be different.

Another huge factor is that hereditary cancers are often treated differently than cancers in the general population. For example, a specific class of drugs, PARP Inhibitors are often used to treat BRCA carriers. Hereditary cancers are often more aggressive, too, and, as a result, may be treated more aggressively. Schlager explained,

If you develop, for instance, cancer in one breast and you have a mutation, it’s very likely you’re going to be advised to remove both breasts, just because the risk of getting breast cancer in that other breast is much higher than the average population.

Navigating Cost

Anoter important consideration tied to access to knowledgeable healthcare providers is cost.

This comes into play when navigating downstream care for hereditary cancer risk because, as Schlager pointed out in the case of breast cancer risk, screenings such as mammograms may be recommended much earlier than for people who are not at high risk in addition to other imaging such as MRIs. “In many cases,” Schlager said, “the insurers are not required to cover these screenings.”

This is because the Affordable Care Act follows the guidelines for screenings recommended for the general population. Insurers may follow the National Comprehensive Cancer Network (NCCN) guidelines, considered, “the best of the best when it comes to hereditary cancer risk management and and also treatment for that matter” according to Schlager.

However, they are not required to by law.

What this can mean, for example, for someone with Lynch syndrome—a mutation said to be responsible for 80 percent of colorectal cancers—is thousands of dollars out of pocket.

The NCCN guidelines recommend that individuals with Lynch syndrome begin screenings at 20 to 25 years of age every one to two years, whereas the general population is recommended to screen once every 10 years beginning at 45.

This presents a huge financial burden for the person with Lynch Syndrome who is tryng to do their due diligence while dealing with an extremely high risk of cancer. Schlager further explained the financial ramifications:

Because it’s not required under the Affordable Care Act, [insurers] will often apply it to the individual’s deductible. So if you have a $5,000 deductible and you go for that colonoscopy at the age of 25, it doesn’t have to be covered under the Affordable Care Act, because the [ACA] only covers screenings that are appropriate for the average risk American. So they don’t have to cover colonoscopy until you’re 45.

Another consideration is the issue of passing a mutation on to children. In such cases, IVF can be used in tandem with Pre Implantation Genetic Diagnosis (PGD) to determine if the embryos carry the mutation. However, outside of the state of Illinois, which recently passed a law to provide coverage for this service, PGD isn’t typically covered. Schlager further explained the levity of this circumstance with regard to fertility preservation:

It’s not only for somebody who’s diagnosed with cancer, which is critical, but for families that have these mutations, especially if a woman is facing removing her ovaries. Maybe she hasn’t had her family yet, and she wants to preserve that option for the future, but she’s feeling pressure. She could harvest her eggs and keep her uterus and still carry a baby in the future.

The Work

FORCE

Force’s work focuses on previvors, medically referred to as “unaffected carriers,” as well as cancer survivors with an identified mutation or strong family history. The organization helps patients and providers know what the options for prevention/care are and make informed decisions with their health care team.

FORCE’s support groups offer community and connection for those navigating hereditary cancer risk, whether as a previvor, survivor, or a relative of a person with an identified mutation. Peer navigators offer support and resources at the individual level, too, as well as message boards and the helpline.

Schlager highlighted the importance of this outreach work that is central to FORCE’s mission and commitment to ensuring that people are not alone in navigating the complex hereditary cancer landscape. Feelings of anger and guilt often accompany the experience of learning of hereditary cancer risk as well as body image issues, social-emotional challenges, and sensitive family dynamics.

Schlager emphasized that while FORCE partners with many organizations doing great work advocating for the needs of individuals facing breast and other forms of cancer, FORCE is the only organization specifically addressing the needs of individuals at risk for hereditary cancers.

Advocacy

The current focus of Schlager’s advocacy work at FORCE, in addition to increasing access to care, is affordable access to screenings and banning genetic discrimination in life, long-term care, and disability insurance. Schlager shared a recent win with regard to affordable access to screenings:

We passed a law, working with partners in Maryland last year, so any high risk breast screening, whether it be ultrasound, MRI, as well as diagnostic exams or if they find something suspicious, is now covered with zero cost to the patient. And we’re trying to pass laws like this all over the country.

As for genetic discrimination, Florida banned the use of genetic information for any instance four years ago and has what Schlager considers the model law. FORCE is now working to duplicate this law in other states.

What You Can Do

FORCE is the only organization that specifically focuses on the hereditary cancer community. Here’s how you can help:

  1. Donate. Money always helps.
  2. Participate in medical research.
  3. Volunteer. Become a peer navigator, support group leader, or research advocate.
  4. Support Policy Work. Support efforts at the federal and state level around access to care and genetic discrimination by calling or emailing representatives or speaking at events.
  5. Share your story: if you have an experience being denied coverage, let FORCE know. It will help efforts to expand laws and protections against genetic discrimination.

Breast Cancer Awareness Month Resources

Schlager offered these final thoughts:

We try to help people make lemonade out of lemons, to know that there are things they can do to manage their risk, and that knowledge gives them power to take control of their health as much as possible.

For further information, visit the following links:

Cevia Yellin
Cevia Yellin Writer

Cevia Yellin is a freelance writer based in Eugene, Oregon. She studied English and French literature as an undergraduate. After serving two years as an AmeriCorps volunteer, she earned her master of arts in teaching English to speakers of other languages. Cevia's travels and experiences working with students of diverse linguistic and cultural backgrounds have contributed to her interest in the forces that shape identity. She grew up on the edge of Philadelphia, where her mom still lives in her childhood home.